C-SU9CresTORbio
beauty content, product comparisons, affiliate publishing
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-SU9C
C-SU9CC-SU9Cbeauty content, product comparisons, affiliate publishing
0-100 chain-logic scale · 15 dimensions · scored on public evidence
The proposed trial will obtain preliminary data on the feasibility of studying RTB101 as compared to placebo for COVID-19 post-exposure prophylaxis in adults age ≥ 65 years to inform the design of a subsequent pivotal trial.
The purpose of this study is to determine if prophylaxis with RTB101 decreases the severity of laboratory-confirmed COVID-19 among adults ≥ 65 years who reside in a nursing homes in which one or more residents or staff have laboratory-confirmed COVID-19
The purpose of this study is to determine if RTB101 prevents illness associated with respiratory tract infections in people ≥65 years of age.
To determine if RTB101 as compared to placebo decreases the percentage of subjects with clinically symptomatic respiratory illness (with or without an associated laboratory-confirmed pathogen) through Week 16.
The purpose of this study is to evaluate the efficacy, tolerability, and safety of BEZ235 alone and in combination with RAD001 to support further development to reduce the incidence of respiratory tract infections (RTIs) in elderly subjects.
Adicet Announces Completion of Merger with resTORbio - aMoon WE believe portfolio alpha TEAM IMPACT news & INSIGHTS Adicet Announces Completion of Merger with resTORbio Contact Careers terms of service privacy policy Ra'anana, Israel © aMoon Website by nym. Developed by Rabbi Interactive
--> Organization | resTORbio, Inc. --> Open Menu Center for Research Innovation in Biotechnology (CRIB) College of Pharmacy in collaboration with --> Clinical Drug Experience Knowledgebase Back Close Menu Drugs Drugs Search by Name FDA Approval Trends Advanced Search FDA Approved Drugs Orgs Orgs Search by Name Organization Trends Advanced Search Indications Indications Search by Name Mechanisms Mechanisms Trials Trials FDA Approvals FDA Approvals About CDEK About CDEK Glossary Advanced Search Guide Search by Name More --> resTORbio, Inc. Report
Workup of Severe Asthma - King's College London Skip to main navigation Skip to search Skip to main content King's College London Home Search content at King's College London Home Profiles Research units Research output Projects Student theses Activities Datasets Impacts Prizes Workup of Severe Asthma Simon Couillard , David J. Jackson , Michael E. Wechsler , Ian D. Pavord * * Corresponding author for this work Peter Gorer Department of Immunobiology Nuffield Department of Clinical Medicine Université de Sherbrooke, Faculté de Médecine et des Sciences de la Santé GSTT Guy's and St Thom … ve reported to CHEST the following: S. C. has received a nonrestricted research grant from Sanofi Genzyme for investigator-initiated type 2 innovation research; speaker honoraria from Sanofi Regeneron, AstraZeneca, and GlaxoSmithKline (GSK), outside the submitted work. D. J. J. has received advisory board and speaker's fees from AstraZeneca, Boehringer Ingelheim, Novartis, Teva, and GSK, Sanofi/Regeneron and Chiesi, outside of the submitted work. M. E. W. reports grants and p … rom Boehringer Ingelheim, GSK, AstraZeneca, Teva, and Chiesi. He has received a grant from Chiesi to support a phase 2 clinical trial in Oxford. He is co-patent holder of the rights to the Leicester Cough Questionnaire and has received payments for its use in clinical trials from Merck, Bayer, and Insmed. In 2014-2015, he was an expert witness for a patent dispute involving AstraZeneca and Teva. Other contributions: The authors thank Dr Timothy SC Hinks for assistance in crea … ve reported to CHEST the following: S. C. has received a nonrestricted research grant from Sanofi Genzyme for investigator-initiated type 2 innovation research; speaker honoraria from Sanofi Regeneron , AstraZeneca , and GlaxoSmithKline (GSK), outside the submitted work. D. J. J. has received advisory board and speaker{\textquoteright}s fees from AstraZeneca , Boehringer Ingelheim, Novartis , Teva, and GSK, Sanofi / Regeneron and Chiesi , outside of the submitted work. M. E. … rom Boehringer Ingelheim, GSK, AstraZeneca, Teva, and Chiesi. He has received a grant from Chiesi to support a phase 2 clinical trial in Oxford. He is co-patent holder of the rights to the Leicester Cough Questionnaire and has received payments for its use in clinical trials from Merck, Bayer, and Insmed. In 2014-2015, he was an expert witness fo
BioCentury - Adicet to become public company via resTORbio merger This Edition ARTICLE | Deals Adicet to become public company via resTORbio merger Paul Bonanos, Associate Editor April 30, 2020 1:10 AM UTC Updated on May 11, 2020 at 3:27 PM UTC Cell therapy developer Adicet will merge with resTORbio to form a public company that will trade under Adicet’s name. The combined company will develop Adicet Bio Inc. ’s pipeline of allogeneic γδ T cell therapies, including ADI-001 for non-Hodgkin lymphoma. The therapy is a CAR-T cell therapy targeting CD20... BCIQ Company Profiles Adicet Bio Inc. resT
resTORbio and Adicet Bio Announce Merger Agreement to --> Accessibility: Skip TopNav resTORbio and Adicet Bio Announce Merger Agreement to Advance Allogeneic Gamma Delta CAR-T Cell Therapy Technology April 29, 2020 07:00 ET | Source: resTORbio, Inc. resTORbio, Inc. Combined Company to Focus on Adicet’s Technology and Continue Operations as “Adicet Bio” Adicet’s lead asset ADI-001 is an allogeneic gamma delta T cell therapy expressing a chimeric antigen receptor targeting CD20 for treatment of non-Hodgkin’s lymphoma Pipeline of differentiated pre-clinical and discovery programs leveragin … n Series B financing in October 2019 and was backed by OrbiMed Advisors, aMoon2 Fund, Novartis Venture Fund, Regeneron Pharmaceuticals, Inc., Johnson & Johnson Innovation – JJDC, Inc. (JJDC), OCI Enterprises, Inc, KB Investment Co., Ltd., Consensus Business Group, SBI JI Innovation Fund, Samsung Venture Investment Corporation, Handok, Inc., DSC Investment, Inc. and Pontifax. In August 2016, Adicet entered into a strategic collaboration with Regeneron focused on developing … ncial performance, results of operations or sufficiency of capital resources to fund operating requirements; future Nasdaq listing; expectations regarding the combined company’s focus, operations, resources and development plan; expectations regarding synergies resulting from the transaction; the executive and board structure of the combined company; expectations of the potential impact of COVID-19 on strategy, future operations, and the timing of clinical trials and timing r … icet’s clinical trials; (xv) the timing of any planned investigational new drug application or new drug application; (xvi) Adicet’s plans to research, develop and commercialize its current and future product candidates; (xvii) Adicet’s ability to enter into new collaborations, and to fulfill its obligations under any such collaboration agreements; (xviii) the clinical utility, potential benefits and market acceptance of Adicet’s product candidates; (xix) Adicet’s commercializ
resTORbio, Inc. Pink Sheet Scrip Medtech Insight HBW Insight Generics Bulletin In Vivo Sign In Free Trial Sign In Free Trial Pink Sheet Scrip Medtech Insight HBW Insight Generics Bulletin In Vivo resTORbio, Inc. https://www.restorbio.com Industry Pharmaceuticals Biotechnology See more in Biomedtracker Latest on resTORbio, Inc. Already A Biomedtracker Subscriber? You have access to the full company record through your subscription. Go To Biomedtracker Twitter feed RSS feed RSS feed Podcast Spotify About About Us Opens in new window Meet the Team Editorial Standards Award-Winning Journalism Help
PureTech's resTORbio Licenses Phase II-Stage Novartis Immunosenescence Drugs genprowebdirectory End Meta Pixel Code --> Facebook Linkedin RSS Twitter Youtube GEN Edge Featured News Multimedia Content News Insights Topics Artificial Intelligence Bioprocessing Cancer Drug Discovery Genome Editing Infectious Diseases OMICs Translational Medicine Magazine Browse Issues Subscribe Multimedia Summits Webinars GEN Live Learning Labs Podcasts Videos Resources A-Lists eBooks/Perspectives Tutorials Peer-Reviewed Journals GEN Biotechnology Re:Gen Open New Products Subscribe Get GEN Magazine Get GEN e
Podcast resTORbio en Amazon Music Inicio Inicio Podcasts Podcasts Biblioteca Cancelar Iniciar sesión resTORbio Podcast restorbio Seguir Welcome to https://www.restorbio.com/ - resTORbio is an advanced clinical stage company, developing medicines to treat aging-related diseases and conditions. CEO & Co-Founder Chen Schor , Joan Mannick, Co-Founder, Chief Medical Officer , resTORbio will become a beauty and health care blog in the future. Thank all guys #resTORbio #ChenSchor read less Health & Fitness Health & Fitness Empieza aquí There is some speculation that Bath & Body Works … you seeking the ILIA foundation review? ILIA’s True Skin Serum Foundation is an award-winning light to medium coverage foundation. This foundation works to even out skin tone, blur the appearance of imperfections and give your face a healthy-looking, radiant glow. ILIA Foundation can be applied alone or over makeup to enhance your natural look […]. Read more: https://www.restorbio.com/ilia-foundation-review/ 4" icon-name="play" show-play-button="" primary-text="Check Out Our … you seeking the ILIA foundation review? ILIA’s True Skin Serum Foundation is an award-winning light to medium coverage foundation. This foundation works to even out skin tone, blur the appearance of imperfections and give your face a healthy-looking, radiant glow. ILIA Foundation can be applied alone or over makeup to enhance your natural look […]. Read more: https://www.restorbio.com/ilia-foundation-review/" duration="" label="" image-src="https://m.media-amazon.com/images/S … you seeking the ILIA foundation review? ILIA’s True Skin Serum Foundation is an award-winning light to medium coverage foundation. This foundation works to even out skin tone, blur the appearance of imperfections and give your face a healthy-looking, radiant glow. ILIA Foundation can be applied alone or over makeup to enhance your natural look […]. Read more: https://www.restorbio.com/ilia-foundation-review/ If you’re looking for a foundation that will give you a natural look
Updates on Advanced Breast Cancer: Local Management and Other New Perspectives - UT MD Anderson - Continuing Education (CE) {1} ##LOC[OK]## {1} ##LOC[OK]## ##LOC[Cancel]## {1} ##LOC[OK]## ##LOC[Cancel]## Return to UT MD Anderson Sign In Home Live On-Demand RSS/Grand Rounds Non-Accredited About Contact Us Help {1} ##LOC[OK]## {1} ##LOC[OK]## ##LOC[Cancel]## {1} ##LOC[OK]## ##LOC[Cancel]## UT MD Anderson workforce members: Select " UT MD ANDERSON LOGIN" and enter your UT MD Anderson email address and password. Guests (all other than UT MD Anderson workforce members): Select "GUEST LOGIN" a … Forgot Your Password? Forgot Your Password? Enter your Email address and click submit to have a login reset link sent to you. Back to Login {1} ##LOC[OK]## {1} ##LOC[OK]## ##LOC[Cancel]## {1} ##LOC[OK]## ##LOC[Cancel]## Create an Account: (All fields are required) Email: First Name: Last Name: Password: Password: Password Requirements Must be between 8 and 16 characters in length Must Contain at least 1 upper case character Must Contain at least 1 lower case character Must c … d provide appropriate delivery of therapy that involves multidisciplinary care. Apply the updated management of locally advanced, recurrent breast cancer. Apply the updated personalized care for metastatic breast cancers, and refer patients to an appropriate clinical trial. Apply the updated knowledge on new biological findings/genomic information into the clinical translation. Registration The two-day Updates on Advanced Breast Cancer: Local Management and other New Pe … to arrival at the conference. https://mdanderson.cloud-cme.com/default.aspx The deadline for advanced registration is Wednesday, April 29, 2022. CONFERENCE REGISTRATION FEES Physicians – MDs (Non-Hal, TMC Members) - Before April 29, 2022 - $50.00 Physicians – MDs (Non-Hal, TMC Members) - After April 29, 2022 - $70.00 Physicians – MDs (Hal, TMC Members, MDACC) - Before April 29, 2022 - $35.00 Physicians – MDs (Hal, TMC Members, MDACC … ng to disclose Rachel M. Layman, MD Professor MD Anderson Cancer Center Faculty Grant or research support-Lilly USA, LLC|Paid consultant-Lilly USA, LLC|Grant or research support-Novartis Pharmaceuticals Corporation|Paid consultant-Novartis Pharmaceuticals Corporation (Relationship has ended)|Grant or research support-Pfizer Inc.|Grant or research
Data Science Day Toggle navigation Home About Overview Structure & Leadership Society Council Committees Treasury Team IT Team Newsletters Contact Information By-laws News Events Upcoming Events Past Events Symposiums NERDS Statathon NextGen : Data Science Day PharmaDS Gallery Conduct Policy Committees Education Journal and Publication NextGen Conferences Strategies and Development Awards/Scholarships Herman Chernoff Award NESS Student Research Awards NESS Student Poster Awards NextGen Scholarship Journal Resources Pfizer Colloquium & ASA Films Ness Colloquium Series Membership Support Donatio … s Colloquium Series Membership Support Donation Sponsorship Payments Honorarium Award Reimbursement Thanks for making a donation to NESS! Your donation will help to promote the growth and expansion of statistical science in the New England area and beyond. Should you have any question or concern, don't hesitate to contact us ( [email protected] ). Cancel NextGen: Data Science Day Home NextGen Data Science Day + Sponsorship + Poster Awards + Keynote/Poster Abstracts + Speak
With Positive Phase 2b Results In Hand, resTORbio CEO Sees Path To 2020 NDA - Benzinga Benzinga España Italia 대한민국 日本 Français My Account Benzinga Edge Benzinga Research Benzinga Pro Login Get Benzinga Pro Data & APIs Events Premarket Advertise Contribute España Italia 대한민국 日本 Français Login Register Benzinga Premium Services Financial News Financial News Large Cap Stocks Small-Cap Stocks Insider Trades Earnings Technology AI News Personal Finance ETF News Crypto News Dividend News Latest Rumors Latest Offerings News Investment Ideas Investment Ideas Stock of the Day Stock Whisper Index An … two pivotal clinical studies in 2019 and get on track for a 2020 NDA (New Drug Application) filing. “I think we’re very well positioned to progress this toward approval,” Schor said. After that point, the drug could be marketed to 24 million targeted RTI patients in the U.S. and 75 million across Europe and Japan. A partnership path for international distribution is under consideration. “In the U.S., I think we may be able to commercialize it ourselves,” Schor said. “Outside … lents, and Schor doesn’t expect to need more funding anytime soon. “That should fund us through 2020, so that would fund the two pivotal studies that I mentioned — that would fund at least one proof-of-concept Phase 2 and potentially bring us to filing the NDA should the Phase 3 work." The firm’s IPO lockup period expired Wednesday, and the stock waned from intraday highs to trade up 65 percent on the day. resTORbio shares were trading down 4.6 percent Thursday afternoon
Partner Event: Wake Forest 2020 William R. Hazzard, MD Translational Research in Aging Symposium: COVID-19 and Older Adults - American Federation for Aging Research MENU CLOSE About AFAR Mission and History Scientific Leadership Board of Directors Staff Recent Annual Reports Policies Job Openings Events JOIN US: Upcoming Events WATCH AGAIN: Archived Webinars News & Views AFAR Experts in the News Ask the Expert Interviews 2025 Grantee Spotlight Interviews Press Releases Special Reports For Scientists Funding Opportunities Dorothy Dillon Eweson Lecture Series 2025 Grant Recipients Past Grant … ding Updates Newsletter Contact Group Initiatives Advancing Research by funding Grant Programs and Fellowships Driving Innovation by guiding studies such as the FAST Initiative , the SuperAgers Initiative , and the TAME Trial Furthering the Field by supporting the infrastructure of three NIA Initiatives and leading the Amplifying Geroscience Initiative . Impact Top Breakthroughs driven by AFAR Experts Delaying Disease by Targeting Aging Saving Costs by Extending Healthspan Le … Why AFAR, Why Aging Research More Ways to Give Give With Confidence Initiatives Grant Programs Clarence Pearson Fellowship TAME Trial NIA Infrastructure Support The SuperAgers Initiative Amplifying Geroscience Initiative FAST Initiative Impact Breakthroughs by AFAR Experts News Events Publications Press Releases Learn What are the Hallmarks of Aging? What is the Longevity Dividend? Ask the Expert Interviews AFAR Webinars Next Avenue Columns What is Geroscience? 2025 GIVE Dona
%PDF-1.6 %���� 772 0 obj > endobj 779 0 obj >/Filter/FlateDecode/ID[ ]/Index[772 13]/Info 771 0 R/Length 56/Prev 2412515/Root 773 0 R/Size 785/Type/XRef/W[1 2 1]>>stream h�bbd``b`�$C�C�`Nq��� @Bљ���y2H�������_���� endstream endobj startxref 0 %%EOF 784 0 obj >stream h��V{LSW?�������t81T���`�gG'a�VEe 8Q��5�&fQwk���J� QS6^C�@X�,�eK�.>��m)3 �b�e� f�9���ފ���c%��������}M��8 i@ �$@>,)�_?�p{n��_��F���� �ڡ%c/�j�Q�����rB���og턵ڭTm��.���`��_ZF\ �S��MU��u�Y��q���H}��o��5 �g��O�o��밞Ե M�?\�%ִ5�R ���� ��Qmž��I�"����ib�ޝ�8� ���c�ϼ( �ޑ���Ӻ��\ �Y���m�1����FZk��P�F ��-)�y��� … 5݉}�����8�� ͤd�${�_$��C:������L�[u�&�n��_�V-,g �.b2 ����b� �٫��-�']�%wf�2(�Rfp+u�@�������9� �"T쌁C�6eS�X���*����+�j�Ý� ����!P�6��Z��u�y�H�H�DS��q�(��Z�oZ �Y ���S �N�(����3 O)09�u���A�I ����w��6s��ݼ�J�KV�wh�Ic�s���ҟ��L��'�@��ml���ɹps�y�/S-#��$��%ktM$��ʤ�ԛ�%� �}��%Bw�P{�m;nuc��=�.�o��K�o��Ĝx�v ��Y��h ��Oy���x�5C+���|��z��0Qa�T�J�+uO�ě�Gϟ���i��F� �q����`J��9��CML�!�a@�/_C>��|/9|)!��(�����_���D�\(�B��Ʊ��k���M�'�[~�0��W���,� �� ߛ�wnD�`�A … h�27�P0P07�T02P����+�-��(���ł�]�� �Z w endstream endobj 545 0 obj >stream application/pdf nmiller Microsoft Word - ACET-2024 Annual Report PScript5.dll Version 5.2.2 2025-04-29T12:39:10-04:00 2025-04-29T12:39:10-04:00 Acrobat Distiller 25.0 (Windows) uuid:bb270746-3c90-4b23-b9c9-30f6a06f5720 uuid:fdd8dcd4-5cb5-4637-a6f5-3bb64061fbcc endstream endobj 546 0 obj >stream hޜ�͊�@�_���v�� �q�f܉�/�F�хoo'�Ea@ƛ�IB�_u�� ���C��%Z��R+:�w/^ui������t=��t�1��Y����j�V4)�ے���mM�"Q�
0001193125-18-010514 Sample Contracts | Law Insider Book a Demo Sign In Sign Up AI Assistant Word Add-In Search Clauses Resources About Pricing Home Sample Contracts 0001193125-18-010514 AI-Powered Contracts Draft, Review & Redline at the Speed of AI 0001193125-18-010514 Sample Contracts resTORbio, Inc. (a Delaware corporation) [●] Shares of Common Stock UNDERWRITING AGREEMENT Underwriting Agreement • January 16th, 2018 • resTORbio, Inc. • Pharmaceutical preparations • New York Contract Type Underwriting Agreement Filed January 16th, 2018 Company resTORbio, Inc. Industry Pharmaceutical pre … re, of the Company (“Common Stock”) set forth in Schedule A hereto and (ii) the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2(b) hereof to purchase all or any part of [●] additional shares of Common Stock. The aforesaid [●] shares of Comm View Source View Similar ( 958 ) Split View RESTORBIO, INC. FORM OF DIRECTOR INDEMNIFICATION AGREEMENT Director Indemnification Agreement • January 16th, 2018 • resTORbio, In
Longwood Fund - David Steinberg About Portfolio Team Press Investor Login Industry Events About Portfolio Team Press Investor Login Industry Events Go back to team Page David Steinberg MBA General Partner Bio David Steinberg is a General Partner at Longwood Fund. He is currently Chairman of the Board of Longwood portfolio companies Photys Therapeutics and Be Biopharma, where he also served as founding Chief Executive Officer, and serves on the board of Longwood portfolio companies AAVantgarde Bio, Carbon Biosciences, Lassen Therapeutics, and Rectify Pharmaceuticals. Previously, he was co-found … School of Business and holds a BA in biology from Cornell University. Longwood Fund The Prudential Tower 800 Boylston Street Suite 1715 Boston, MA, 02199 About Portfolio Team Press Investor Login Industry Events © Longwood Fund. All Rights Reserved
%PDF-1.7 %���� 4235 0 obj > endobj 4266 0 obj >/Filter/FlateDecode/ID[ ]/Index[4235 68]/Info 4234 0 R/Length 142/Prev 3821350/Root 4236 0 R/Size 4303/Type/XRef/W[1 3 1]>>stream h�bbd```b``�� sA$�;�uDJ��H +0Y &߀ɫ`2 D2_�� � l��o)~DJ��_$��Al�c ��L>�Mۥ"��@$[?��2��0-��g�� ���.g` &��O��*�� endstream endobj startxref 0 %%EOF 4302 0 obj >stream h�b```f``����� ��A�DX�X8� dXX�1p1*�02(p06X004�lP�Խ� �CmK�:����%��1z�ضo� )6���y�'�'S�=e� �TY����"��x��s��>�u={Sd����OV��0�z�q�%��5,�8��4���1��3�In j&��'!g�wJ|�D�� ��'EN7�25����]sx���BKT��ń�'?�]�!ϡ�*��sxГ���}˦ … \��X����� �������8��Yt �����.}��Y�{�F�.�]Y�'���ԭ� ��� �^ư��L��1��� >stream application/pdf ATS2020-logo-Horiz_blue-gray2-NEW 2019-03-08T16:05:30-05:00 2019-03-08T16:05:30-05:00 2019-02-19T17:18:08-05:00 Adobe Illustrator CC 23.0 (Macintosh) uuid:be51fa27-40ef-be4f-89b2-f5e46b929c0a xmp.did:01b7b332-c3ad-4e79-8def-bee7a5eaeed8 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:a7fcefaf-eaa6-4ede-9a23-2b4386eb20c8 xmp.did:a7fcefaf-eaa6-4ede-9a23-2b4386eb20c8 uuid:5D20 … 14EE958FF8CE96 2012-06-04T15:06:21-04:00 Adobe Illustrator CS5 / converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:677ae80c-630a-45ad-85a6-5611486b0ab6 2015-01-05T10:50:49-05:00 Adobe Illustrator CC (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator con … from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:e41a8b98-c9cd-4cf2-8cdc-ba37f9c5900a 2016-12-19T19:07:32-05:00 Adobe Illustrator CC 2015 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:856fcf81-af1a-41bf-86d9-f9cc65a13a25 2017-06-13T13:13:35-04 … 017-06-13T13:13:35-04:00 Adobe Illustrator CC 2017 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:ab098217-584c-40f6-9d70-c6cbe7883e9e 2018-03-13T19:29:05-04:00 Adobe Illustrator CC 22.0 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:62
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
Our Pipeline - Restore Skin and Hair with Product Comparison Skincare Body Hair Make-up Massage About Restorbio Shop Contact Skincare Body Hair Make-up Massage About Restorbio Shop Contact Press ESC to close Or check our Popular Categories... Skincare Hair Body Make-up Massage Gua Sha Our Pipeline We are a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases. Our lead program selectively inhibits the activity of a protein complex called target of rapamycin complex 1, or TORC1, an evolutionarily cons … For Parkinson’s disease, we may be required to file an investigational new drug application, or IND, prior to initiating Phase 2 clinical trials ** For neurodegenerative diseases and diseases associated with TORC1 hyperactivation, subject to review by the U.S. Food and Drug Administration, we believe we may have the ability to initiate Phase 2 clinical trials without the need to conduct additional Phase 1 trials. Check out on Cerave vs La Roche Posay . Contents About RTB101 A
Adicet Bio, Inc. (Form: 8-K, Received: 09/16/2020 10:02:54) --12-31 false 0001720580 0001720580 2020-09-15 2020-09-15     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2020     Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter)       Delaware   001-38359   81-3305277 (State or Other Jurisdiction of Incorporation)   … cet (the “Investors”), pursuant to which the Investors committed to fund up to an aggregate of $15,000,000 (the “Funding Amount”) into an escrow account, which will be used to subscribe for shares of the Company’s common stock, par value $0.0001 per share (the “Company Common Stock”) in a concurrent private placement in connection with a private placement or public offering of Company Common Stock for aggregate gross proceeds (includi … n a fully-diluted basis (in each case excluding equity incentives available for grant). The shares of Company Common Stock listed on the Nasdaq Global Market, previously trading through the close of business on September 15, 2020 under the ticker symbol “TORC,” will commence trading on the Nasdaq Global Market, on a post-Reverse Stock Split adjusted basis, under the ticker symbol “ACET,” on September 16, 2020, at which time the Company Common … 19. Dr. Schindel is the Managing Partner and Co-Founder of aMoon Fund, an investment house focused on accelerating cure in healthcare and life sciences. Prior to his time at aMoon, Dr. Schindel was the founding CEO of “Digital Israel”, the State of Israel’s National Digital Bureau which was setup at the Prime Minister’s Office to accelerate digital transformation nationally. Dr. Schindel was also the founder of the MAOZ Network … nal Medicine, Rheumatology & Immunology at BWH and a post-doctoral research fellowship at the Center for Blood Research in Boston. Carrie Krehlik, M.B.A., Senior Vice President and Chief Human Resources Officer Ms. Krehlik has served as Adicet’s Senior Vice President and Chief Human Resource Officer since November 2017. From July 2
Aveeno Vs Cerave: Cleansers, Moisturizers, Serum, Eye Cream and Sunscreen Comparison - Restore Skin and Hair with Product Comparison Skincare Body Hair Make-up Massage About Restorbio Shop Contact Skincare Body Hair Make-up Massage About Restorbio Shop Contact Press ESC to close Or check our Popular Categories... Skincare Hair Body Make-up Massage Gua Sha Aveeno Vs Cerave: Cleansers, Moisturizers, Serum, Eye Cream and Sunscreen Comparison 21 Min Read Last Update: May 5, 2026 Aveeno and Cerave are both popular brands of skincare products. They both contain ceramides, which are lipid molecules t … ry, sensitive skin. It will moisturize for 24 hours, so you don’t have to apply it too often. The light, non-greasy formula is quickly absorbed, hypoallergenic, and fragrance-free, making it safe for children of all ages. Aveeno is a clinically proven brand with one key ingredient: natural colloidal oatmeal. This ultra-moisturizing component helps restore the pH balance of your baby’s skin and prevent dryness. These two brands are better in different areas. … y, and non-comedogenic, making it gentle enough for everyday use. You can apply Aveeno as often as needed, particularly after washing. Some people may need to moisturize several times daily, but this lotion is up to the task. Additionally, if you suffer from eczema or other conditions that cause dry skin, using a moisturizer like Aveeno regularly can help prevent flare-ups. Do dermatologists recommend Aveeno? Deciding whether or not to invest in Aveeno skincare pr
Restore Skin and Hair with Product Comparison - Restore Beauty - Rethink Bio Skincare Body Hair Make-up Massage About Restorbio Shop Contact Skincare Body Hair Make-up Massage About Restorbio Shop Contact Press ESC to close Or check our Popular Categories... Skincare Hair Body Make-up Massage Gua Sha Can I Use Olive Oil to Remove Makeup? Skincare 7 Min Read One of the most difficult tasks you have to perform every day is taking off your… Continue Reading Baking Powder vs Setting Powder Make-up 7 Min Read It might be challenging to choose which sort of powder is appropriate for your needs
--> Forward-Looking Statements This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding: the exp --> Login Start Free Trial Catalyst Calendar FDA Calendar Track key readouts and FDA decision dates in biotech and pharma. BPW Portfolio Bio Hedge Fund Shots and more... Historical FDA Calendar Review past FDA decisions and clinical readouts. Market Movers Track today's biotech market movers Biotech Earning Calendar Stay updated on biotech earnings. Historical PDUFA Dates … p; past IPOs. Bio Pharma Screener Catalyst Sync™ Track biotech catalysts. Hedge Fund Screener Analyze hedge fund holdings. Company Screener Holistic company & pipeline analysis. All Stocks Holdings Explore hedge fund stock data. Heat-Map Market size & sector heat map. Inside Trades Monitor insider trading. Biotech Analyst Ratings Biotech analyst ratings & price targets M&A Tracker Track M&A deals and acquisition targets Resources News Latest biotech news. … ncial performance, results of operations or sufficiency of capital resources to fund operating requirements; future NASDAQ listing; expectations regarding the combined company's focus, operations, resources and development plan; expectations regarding synergies resulting from the proposed merger transaction; the executive and board structure of the combined company; expectations of the potential impact of the COVID-19 pandemic on resTORbio, Inc.'s ("resTORbio"), Adicet Bio, I … icet's clinical trials; (xv) the timing of any planned investigational new drug application or new drug application; (xvi) Adicet's plans to research, develop and commercialize its current and future product candidates; (xvii) Adicet's ability to enter into new collaborations, and to fulfill its obligations under any such collaboration agreements; (xviii) the clinical utility, potential benefits and market acceptance of Adicet's product candidates; (xix) Adicet's commercializ
%PDF-1.7 %���� 7522 0 obj > stream x� endstream endobj 7523 0 obj > stream x� endstream endobj 7520 0 obj > stream x� endstream endobj 7521 0 obj > stream x� endstream endobj 7526 0 obj > stream x� endstream endobj 7527 0 obj > stream x� endstream endobj 7524 0 obj > stream x� endstream endobj 7525 0 obj > stream x� endstream endobj 7530 0 obj > stream x� endstream endobj 7531 0 obj > stream x� endstream endobj 7528 0 obj > stream x� endstream endobj 7529 0 obj > stream x� endstream endobj 7534 0 obj > stream x� endstream endobj 7535 0 obj > stream x� endstream endo … A[�kٌ_�3��,{�=�6�-l+�ƶ��i�} /�ݴ��{��C > stream Microsoft® Word for Office 365 application/pdf Kerry Russell Microsoft® Word for Office 365 2019-09-17T22:51:10-04:00 2021-05-31T04:27:47-04:00 uuid:0C756C47-F1D6-42D4-B305-3AC9FD4CFB73 uuid:53ca285b-bdea-45c7-8d15-97ea90c35122 endstream endobj 7353 0 obj > stream x��} `��������$�d�o��d2�0 ! $�䟕%,aϠ�I¾%�jQb��A-���R�e2 ЯD�uk �}�`�V��Ժ~B�����}}��{��uΝsϽ�{���CH�Q Z��F] ˗�� w�ʵ�Y�\��3D�SWt��� ��B��O �{e�w:3ޱ�.6��� ��j+��
Restore Skin and Hair with Product Comparison - Restore Beauty - Rethink Bio Skincare Body Hair Make-up Massage About Restorbio Shop Contact Skincare Body Hair Make-up Massage About Restorbio Shop Contact Press ESC to close Or check our Popular Categories... Skincare Hair Body Make-up Massage Gua Sha Can I Use Olive Oil to Remove Makeup? Skincare 7 Min Read One of the most difficult tasks you have to perform every day is taking off your… Continue Reading Baking Powder vs Setting Powder Make-up 7 Min Read It might be challenging to choose which sort of powder is appropriate for your needs
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.21.2 Organization and Nature of Business 9 Months Ended Sep. 30, 2021 Organization Consolidation And Presentation Of Financial Statements [Abstract]   Organization and Nature of Business 1. Organization and Nature of the Business Adicet Bio, Inc. (formerly resTORbio, Inc. (resTORbio)), together with its subsidiaries, (the Company) is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. The Company is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered w … n a fully-diluted basis (in each case excluding equity incentives available for grant). The Company concluded that the transaction represented a business combination pursuant to Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 805, Business Combinations . Further, Former Adicet was determined to be the accounting acquirer based upon the terms of the Merger and other factors including: (i) Former Adicet’s securityholders own appro … ned company (on a fully-diluted basis excluding equity incentives available for grant); (ii) Former Adicet designated a majority (five of seven) of the initial members of the Board of Directors of the combined company; and (iii) the terms of the exchange of equity interests based on the exchange ratio at the announcement of the Merger factored in an implied premium to resTORbio’s stockholders. The composition of senior management of the combined company was determined t … n a fully-diluted basis (in each case excluding equity incentives available for grant). Please refer to Note 3 “Business Combinations” for further details of the Merger. Liquidity The Company has incurred significant net operating losses and negative cash flows from operations and has an accumulated deficit of $ 152.5 million as of September 30, 2021. The Company has historically financed its operations primarily through a collaboration and licensing arrangement, … stock purchase agreement with certain existing investors, will be sufficient to fund its forecasted operating expenses, capital expenditure requirements and debt service payments for at least the next twelve months from the issuance of these interim consolidated financial statements. All of the Company’s revenue to date is generated from th
561 Therapeutics Companies Worldwide | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas Therapeutics 548 Employers in 854 locations Employers working on Therapeutics work in 189 other areas Displaying 1 - 50 of 189 related areas Show: 15 50 All Antibodies (86) Microbiome (64) Small Molecules (57) Biologics (33) COVID-19 (29) Cell and Gene Therapy (28) Neurobio
resTORbio Presents Additional Phase 2b Data at the American Thoracic Society International Conference for RTB101 as a Potential Immunotherapy to Reduce the Incidence of Respiratory Tract Infections - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development resTORbio Presents Additional Phase 2b Data at the American Thoracic Society International Conference for RTB101 as a Potential Immunotherapy to Reduce the Incidence of Respiratory Tract Infections May 21, 2019 | 6 min read Twitter LinkedIn Facebook Email Print RTB101 10 mg once daily … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Restore Skin and Hair with Product Comparison - Restore Beauty - Rethink Bio Skincare Body Hair Make-up Massage About Restorbio Shop Contact Skincare Body Hair Make-up Massage About Restorbio Shop Contact Press ESC to close Or check our Popular Categories... Skincare Hair Body Make-up Massage Gua Sha Can I Use Olive Oil to Remove Makeup? Skincare 7 Min Read One of the most difficult tasks you have to perform every day is taking off your… Continue Reading Baking Powder vs Setting Powder Make-up 7 Min Read It might be challenging to choose which sort of powder is appropriate for your needs
Innovation Centers | Johnson & Johnson Innovation You need to enable JavaScript to run this app.
Restore Skin and Hair with Product Comparison - Restore Beauty - Rethink Bio Skincare Body Hair Make-up Massage About Restorbio Shop Contact Skincare Body Hair Make-up Massage About Restorbio Shop Contact Press ESC to close Or check our Popular Categories... Skincare Hair Body Make-up Massage Gua Sha Can I Use Olive Oil to Remove Makeup? Skincare 7 Min Read One of the most difficult tasks you have to perform every day is taking off your… Continue Reading Baking Powder vs Setting Powder Make-up 7 Min Read It might be challenging to choose which sort of powder is appropriate for your needs
resTORbio | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas resTORbio Website: resTORbio Business Area(s) Therapeutics Description resTORbio, Inc. is a clinical stage company, developing medicines to treat aging-related diseases and conditions. resTORbio’s lead program targets the mechanistic target of rapamycin complex 1 (mTORC1) pathway to treat
--> Forward-Looking Statements This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding: the exp --> Login Start Free Trial Catalyst Calendar FDA Calendar Track key readouts and FDA decision dates in biotech and pharma. BPW Portfolio Bio Hedge Fund Shots and more... Historical FDA Calendar Review past FDA decisions and clinical readouts. Market Movers Track today's biotech market movers Biotech Earning Calendar Stay updated on biotech earnings. Historical PDUFA Dates … p; past IPOs. Bio Pharma Screener Catalyst Sync™ Track biotech catalysts. Hedge Fund Screener Analyze hedge fund holdings. Company Screener Holistic company & pipeline analysis. All Stocks Holdings Explore hedge fund stock data. Heat-Map Market size & sector heat map. Inside Trades Monitor insider trading. Biotech Analyst Ratings Biotech analyst ratings & price targets M&A Tracker Track M&A deals and acquisition targets Resources News Latest biotech news. … ncial performance, results of operations or sufficiency of capital resources to fund operating requirements; future NASDAQ listing; expectations regarding the combined company's focus, operations, resources and development plan; expectations regarding synergies resulting from the proposed merger transaction; the executive and board structure of the combined company; expectations of the potential impact of the COVID-19 pandemic on resTORbio Inc.'s ("resTORbio"), Adicet Bio, In … icet's clinical trials; (xv) the timing of any planned investigational new drug application or new drug application; (xvi) Adicet's plans to research, develop and commercialize its current and future product candidates; (xvii) Adicet's ability to enter into new collaborations, and to fulfill its obligations under any such collaboration agreements; (xviii) the clinical utility, potential benefits and market acceptance of Adicet's product candidates; (xix) Adicet's commercializ … cytokine release syndrome No GvHD ADI-001 Status Pre-IND meeting completed IND application enabling activities in process ADI-001 IND application preparation in process Proposed ADI-001 clinical trial design well received by key centers and KOLs Preparations for ADI-001 Phase 1 Clinical study underway Additional Pipeline in Solid Tumors: Anticip
Restore Skin and Hair with Product Comparison - Restore Beauty - Rethink Bio Skincare Body Hair Make-up Massage About Restorbio Shop Contact Skincare Body Hair Make-up Massage About Restorbio Shop Contact Press ESC to close Or check our Popular Categories... Skincare Hair Body Make-up Massage Gua Sha Can I Use Olive Oil to Remove Makeup? Skincare 7 Min Read One of the most difficult tasks you have to perform every day is taking off your… Continue Reading Baking Powder vs Setting Powder Make-up 7 Min Read It might be challenging to choose which sort of powder is appropriate for your needs
resTORbio halts clinical development of RTB101 in respiratory illness Skip to site menu Skip to page content Switch language: .translate --> CT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Approvals Operations Outsourced Services Supply Chain Data Management Medical Devices Themes Artificial Intelligence Cloud Corporate Governance Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insights Deals Jobs Filings Patents Social Media Companies Company A-Z Company Categories Produc … Chain Data Management Medical Devices Latest Ollin Biosciences secures $330m to fund Phase III OLN324 trials Viking Therapeutics commences Phase I trial of VK3019 Ascletis receives FDA clearance for Phase I trial of obesity treatment Themes Sections Artificial Intelligence Cloud Corporate Governance Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Foreign Direct Investment Latest How wearables can unlock their full potentia
resTORbio, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 08 May 2025 resTORbio, Inc. Public Company | 2016 | Massachusetts, United States | < 10 | NASDAQ: TORC | www.restorbio.com Public Company | 2016 | Massachusetts, United States | < 10 | NASDAQ: TORC | www.restorbio.com Last update 08 May 2025 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Neoplasms Hemic and Lymphatic Diseases Urogenital Diseases Universal CAR-T Small molecule drug T-lym … al trials. In October 2024, the FDA approved the investigational new drug (IND) application for Cullinan Therapeutics' CLN-978 to treat systemic lupus erythematosus (SLE). In September 2024, Cartesian Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to Descartes-08 for the treatment of juvenile dermatomyositis (JDM). In September 2024, Caribou Biosciences announced that the U.S. Food and Drug Administ … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
Restore Skin and Hair with Product Comparison - Restore Beauty - Rethink Bio Skincare Body Hair Make-up Massage About Restorbio Shop Contact Skincare Body Hair Make-up Massage About Restorbio Shop Contact Press ESC to close Or check our Popular Categories... Skincare Hair Body Make-up Massage Gua Sha Can I Use Olive Oil to Remove Makeup? Skincare 7 Min Read One of the most difficult tasks you have to perform every day is taking off your… Continue Reading Baking Powder vs Setting Powder Make-up 7 Min Read It might be challenging to choose which sort of powder is appropriate for your needs
10-K 1 torc-10k_20191231.htm 10-K torc-10k_20191231.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from                      to        … eding 12 months (or for such shorter period that the registrant was required to submit such files).     ☒   Yes    ☐   No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller … * For PD, we may be required to file an investigational new drug application, or IND, with the U.S. Food and Drug Administration, or FDA, prior to initiating Phase 2 clinical trials in the United States. ** For neurodegenerative diseases and diseases associated with TORC1 hyperactivation, subject to review by the FDA, we believe we may have the ability to initiate Phase 2 clinical trials without the need to conduct additional Phase 1 trials. Aging and its Regul … scientific and factual questions. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Consequently, we do not know whether any of our product candidates will be protectable or remain protected by enforceable patents. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the clai … patent term extensions. We believe that patent term extension and the potential grant of certain pending patent applications may provide exclusivity for RTB101 and RTB101 in combination with everolimus until 2039 in the United States and the major European markets. 7 The exclusive field for RTB101 is for the treatment, prevention and diagnosis of
Restore Skin and Hair with Product Comparison - Restore Beauty - Rethink Bio Skincare Body Hair Make-up Massage About Restorbio Shop Contact Skincare Body Hair Make-up Massage About Restorbio Shop Contact Press ESC to close Or check our Popular Categories... Skincare Hair Body Make-up Massage Gua Sha Can I Use Olive Oil to Remove Makeup? Skincare 7 Min Read One of the most difficult tasks you have to perform every day is taking off your… Continue Reading Baking Powder vs Setting Powder Make-up 7 Min Read It might be challenging to choose which sort of powder is appropriate for your needs
resTORbio and Adicet Bio Announce Merger Agreement to Advance Allogeneic Gamma Delta CAR-T Cell Therapy Technology - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job T … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Deals resTORbio and Adicet Bio Announce Merger Agreement to Advance Allogeneic Gamma Delta CAR-T Cell Therapy Technology April 29, 2020 | 14 min read Twitter LinkedIn Facebook Email Print Adicet’s lead asset ADI-001 is an allogeneic gamma delta T cell therapy expressing a chimeric antigen receptor tar … n Series B financing in October 2019 and was backed by OrbiMed Advisors, aMoon2 Fund, Novartis Venture Fund, Regeneron Pharmaceuticals, Inc., Johnson & Johnson Innovation – JJDC, Inc. (JJDC), OCI Enterprises, Inc, KB Investment Co., Ltd., Consensus Business Group, SBI JI Innovation Fund, Samsung Venture Investment Corporation, Handok, Inc., DSC Investment, Inc. and Pontifax. In August 2016, Adicet entered into a strategic collaboration with Regeneron focused on developing … ncial performance, results of operations or sufficiency of capital resources to fund operating requirements; future Nasdaq listing; expectations regarding the combined company’s focus, operations, resources and development plan; expectations regarding synergies resulting from the transaction; the executive and board structure of the combined company; expectations of the potential impact of COVID-19 on strategy, future operations, and the timing of clinical trials and timing r … icet’s clinical trials; (xv) the timing of any planned investigational new drug application or new drug application; (xvi) Adicet’s plans to research, develop and commercialize its current and future product candidates; (xvii) Adicet’s ability to enter into new collaborations, and to fulfill its obligations under any such collaboration agreements
Past Portfolio Companies - NSG Ventures × × What are you looking for? Search for: Category Archives Past Portfolio Companies All Past Portfolio Companies 88 Rising Continue Reading Past Portfolio Companies PairXBio Continue Reading Past Portfolio Companies Black Diamond Continue Reading Past Portfolio Companies Bota Bio Continue Reading Past Portfolio Companies NU Bank Continue Reading Past Portfolio Companies NSG Bio Continue Reading Past Portfolio Companies Restorbio Continue Reading Past Portfolio Companies Enleofen Continue Reading Past Portfolio Companies Tango Continue Readin
This was a blast to record with my friend John Flavin... give it a listen if you're interested in venture creation, entrepreneurship, the perils and pitfalls of fundraising, outlook for the biotech… | David Steinberg LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choic … w! listen here: https://lnkd.in/dvT5bWje David is a general partner at Longwood Fund & chairman of the board of Photys Therapeutics and Be Biopharma . also, as well, he serves on the board of AAVantgarde Bio , Carbon Biosciences , Lassen Therapeutics , and Rectify Pharma (they also r Longwood portfolio companies). previously, he was co-founder and Chief Innovation Officer of biotech venture creation firm PureTech Health (NASDAQ: PRTC), focusing on launching and investing
S-1 Table of Contents As filed with the Securities and Exchange Commission on December 29, 2017. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 resTORbio, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 81-3305277 (State or other jurisdiction of incorporation or organization) (Primary Standard Industri … ertain other infections, we may be required to file an investigational new drug application, or IND, prior to initiating Phase 2 clinical trials. We expect to have the ability to initiate these Phase 2 clinical trials without the need to conduct prior Phase 1 clinical trials. We also have a follow-on TORC1 inhibitor program at discovery stage. We expect market exclusivity for RTB101 alone and in combination with everolimus until at least 2031 in the United States, 2032 i … If our Phase 3 clinical trials are successful, we anticipate filing a New Drug Application, or NDA, with the FDA in 2020, and a Marketing Authorization Application, or MAA, with the European Medicines Agency, or EMA, in 2021. Other Potential Indications for Our TORC1 Program We may evaluate RTB101 alone or in combination with everolimus or other drugs for the treatment of additional indications, such as heart failure with preserved ejection fraction, urinary tract infections … n exemption from new or revised financial accounting standards until they would apply to private companies and from compliance with any new requirements adopted by the Public Company Accounting Oversight Board requiring mandatory audit firm rotation. In particular, in this prospectus, we have not included all of the executive compensation-related information that would be required if we were not an emerging growth company. Accordingly, the information contained herein may be … ds from this offering, together with our existing cash and cash equivalents, to fund the development of RTB101, alone and in combination with everolimus, for RTIs and other indications, and our TORC1 follow-on candidate and other pipeline candidates, and the remainder, if any, for working capital and general corporate purposes. See the “Use
Asset->js('assets/js/cookie-banner', null, false) }}" as="script">--> --> resTORbio’s stock rises after positive trial results for treatment of respiratory tract infections | NASDAQ:TORC @ element('Front/sign_in_out_buttons') --> USA UK USA AU CA Watch --> My Proactive Feed Alerts Subscriptions Bookmarks Settings Sign In News Browse Latest news Live Market reports OTC Markets Small caps Varon CEO discusses Ballislife Hydro Growth - ICYMI 14:30 27 Jun --> Varon Corp is building a next-generation beverage portfolio centered on hydration and wellness 14:30 27 Jun --> Aftermath Silver nears key pr
resTORbio Halts Respiratory Program for RTB101 After Phase III Failure - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development resTORbio Halts Respiratory Program for RTB101 After Phase III Failure November 15, 2019 | 3 min read | Mark Terry Twitter LinkedIn Facebook Email Print The company halted the development of the drug RTB101 for respiratory disease but will continue to test it in other are … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
resTORbio Announces That the Phase 3 PROTECTOR 1 Trial of RTB101 in Clinically Symptomatic Respiratory Illness Did Not Meet the Primary Endpoint - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manu … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development resTORbio Announces That the Phase 3 PROTECTOR 1 Trial of RTB101 in Clinically Symptomatic Respiratory Illness Did Not Meet the Primary Endpoint November 15, 2019 | 5 min read Twitter LinkedIn Facebook Email Print resTORbio, Inc., (Nasdaq: TORC), a clinical-stage biopharmaceutical com … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
resTORbio Announces Interim Results for Phase 1b/2a Trial of RTB101 in Patients with Parkinson’s Disease and Provides Corporate Update - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development resTORbio Announces Interim Results for Phase 1b/2a Trial of RTB101 in Patients with Parkinson’s Disease and Provides Corporate Update February 19, 2020 | 6 min read Twitter LinkedIn Facebook Email Print -- Interim data from three cohorts in the Phase 1b/2a study demonstrate that RTB1 … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
resTORbio Appoints Lynne Sullivan to Its Board of Directors - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Relea … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business resTORbio Appoints Lynne Sullivan to Its Board of Directors January 3, 2018 | 4 min read Twitter LinkedIn Facebook Email Print resTORbio announced that Lynne Sullivan, Senior Vice President of Finance for Biogen, Inc. has joined the resTORbio board of directors as an independent director. Jan … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Boston's Anti-Aging Startup resTORbio Scores $40M - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases A … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Genetown Boston’s Anti-Aging Startup resTORbio Scores $40M November 30, 2017 | 4 min read Twitter LinkedIn Facebook Email Print Counsyl Celebrates Anniversary With $80M F This financing brings the total capital raised this year to $65 million, including a $25 million Series A financing that was completed earlier this ye … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
resTORbio and Adicet Bio Merge to Advance T-Cell Therapies - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releas … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Deals resTORbio and Adicet Bio Merge to Advance T-Cell Therapies April 30, 2020 | 2 min read | Mark Terry Twitter LinkedIn Facebook Email Print The deal is expected to close in the second half of 2020. Once finalized, the combined company will run under the name Adicet Bio and is expected … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Restorbio realises IPO ambitions - Global Venturing Global Venturing | Restorbio realises IPO ambitions Where Global Innovation and Capital Meet Home --> Register Login Go Corporate University Impact Full Site Corporate University Impact Daily Deal Round Up: May 25, 2021 Affirm spinoff Resolve raised $60m from investors including its parent company... Find Out More Daily Deal Round Up: May 25, 2021 Affirm spinoff Resolve raised $60m from investors including its parent company... Find Out More Daily Deal Round Up: May 25, 2021 Affirm spinoff Resolve raised $60m from investors including its pare
424B3 1 d923175d424b3.htm 424B3 424B3 Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-239372 PROPOSED MERGER YOUR VOTE IS VERY IMPORTANT To the Stockholders of resTORbio, Inc. and Adicet Bio, Inc.: resTORbio, Inc. (referred to as “resTORbio”) and Adicet Bio, Inc. (referred to as “Adicet”) have entered into an Agreement and Plan of Merger (referred to as the “merger agreement”) pursuant to which Project Oasis Merger Sub, Inc., a wholly owned subsidiary of resTORbio, will merge with and into Adicet, with Adicet surviving a … n a fully-diluted basis (in each case excluding equity incentives available for grant). Shares of resTORbio common stock are currently listed on The Nasdaq Global Select Market (referred to as “Nasdaq”) under the symbol “TORC.” In connection with completion of the merger, resTORbio will be renamed “Adicet Bio, Inc.” and expects to trade on Nasdaq under the symbol “ACET.” On August 18, 2020, the last trading day before the date of t … 7;change of control” of resTORbio (referred to as the “share issuance proposal” or “Proposal No. 1”); 2) To approve an amendment to resTORbio’s third amended and restated certificate of incorporation to effect a reverse stock split of resTORbio common stock (referred to as the “reverse stock split proposal” or “Proposal No. 2”); 3) To approve an amendment of the resTORbio 2018 Stock Option … ed in connection with the merger (referred to as the “option pool increase proposal” or “Proposal No. 3”); and 4) To approve an adjournment or postponement of the special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal No. 1, Proposal No. 2 and/or Proposal No. 3 (referred to as the “adjournment proposal” or “Proposal No. 4”). As described in this pr … the merger, in the case of Adicet capital stock holders, and the share issuance proposal and the reverse stock split proposal, in the case of resTORbio stockholders, subject to the terms of the support agreements. In addition, following the registration statement on Form S-4, of which this proxy statement/prospectus/information statement is a par
Restore Skin and Hair with Product Comparison - Restore Beauty - Rethink Bio Skincare Body Hair Make-up Massage About Restorbio Shop Contact Skincare Body Hair Make-up Massage About Restorbio Shop Contact Press ESC to close Or check our Popular Categories... Skincare Hair Body Make-up Massage Gua Sha Can I Use Olive Oil to Remove Makeup? Skincare 7 Min Read One of the most difficult tasks you have to perform every day is taking off your… Continue Reading Baking Powder vs Setting Powder Make-up 7 Min Read It might be challenging to choose which sort of powder is appropriate for your needs
Life at resTORbio - Restore Skin and Hair with Product Comparison Skincare Body Hair Make-up Massage About Restorbio Shop Contact Skincare Body Hair Make-up Massage About Restorbio Shop Contact Press ESC to close Or check our Popular Categories... Skincare Hair Body Make-up Massage Gua Sha Life at resTORbio At resTORbio , we are rethinking aging. We are developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases. We are a fast-paced, energetic, innovative, and highly motivated team that wants to lengthen the time we are healthy, active, and disea
resTORbio - Longevity List Sign in or Register Add a listing View all results No results Jobs Database More arrow_drop_down Clinical Trials Newsletter Coworking Events Blog Supporters About Add a listing opening tag is omitted --> tag --> resTORbio Targeting the biology of aging to prevent or treat aging-related diseases. Website Profile prev next Website Bookmark Share prev next General Headquarters Boston, Massachusetts, United States Founders & Team Chen Schor, Joan Mannick Year Founded 2016 Company type Public company Stock Ticker TORC Funding stage IPO Total funding ($M) 65 Technical Deta
resTORbio | Boston Family Office | Altss For Asset Classes Solutions Compare Case Studies Blog Book a demo Home Family Offices Boston resTORbio Family Office Updated: Jun 3, 2026 resTORbio Restorbio is a Boston-based biotechnology firm founded in 2016. It focuses on developing medicines targeting aging biology to prevent or treat age-related... resTORbio Restorbio is a Boston-based biotechnology firm founded in 2016. It focuses on developing medicines targeting aging biology to prevent or treat age-related diseases. The company has received $65 million in total funding. Website restorbio.com L … Preqin Altss vs PitchBook Altss vs FINTRX Altss vs Dakota Company About us Why Submit Data How we Collect Data Press Careers Contribute Submit your firm Submit a deal Submit a fund
492: Dr. Joan Mannick: Investigating Novel Therapeutics to Improve Immune Function and Treat Age-Related Diseases - People Behind the Science Podcast Skip to main content Skip to footer People Behind the Science Podcast Science Podcast - Journey through the minds of today's brilliant scientists About About Contact Scientists Resources Podcasts Podcasts Special Episodes Support 492: Dr. Joan Mannick: Investigating Novel Therapeutics to Improve Immune Function and Treat Age-Related Diseases March 11, 2019 By PBtS Leave a Comment Listen to the Episode Below (00:36:58) 0.75x 1x 1.25x 1.5x 2x … rom Harvard College and her M.D. from Harvard Medical School. She completed her residency in Internal Medicine at Brigham and Women’s Hospital and a fellowship in Infectious Disease at Harvard University. Joan then worked as a Medical Director at Genzyme and a faculty member at Harvard Medical School and the University of Massachusetts Medical School. Prior to joining resTORbio, Joan was Executive Director in the New Indications Discovery Unit of the Novartis Institutes
resTORbio, Inc. Appoints Joan Mannick, M.D., As Chief Medical Officer - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions P … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business resTORbio, Inc. Appoints Joan Mannick, M.D., As Chief Medical Officer April 13, 2017 | 5 min read Twitter LinkedIn Facebook Email Print Expert in the field of aging to oversee clinical-stage mTORC1 program BOSTON--( BUSINESS WIRE )--resTORbio, Inc. (resTORbio), a subsidiary of PureTech Health … rom Harvard College and her M.D. from Harvard Medical School. She completed her residency in Internal Medicine at Brigham and Women’s Hospital and an Infectious Disease fellowship as part of the Harvard Combined Infectious Disease Program. “I am very excited to join resTORbio and continue the development of the mTORC1 program. Two Phase 2a clinical studies have been completed with the program, and I am eager to move the program forward in development and initiate Phase 2b thi … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin